*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Nateglinide</strong> is a rapid-acting meglitinide derivative used to manage postprandial hyperglycemia in type 2 diabetes. It acts by stimulating insulin secretion from pancreatic beta cells via ATP-sensitive potassium channels. The standard pharmaceutical synthesis involves condensation reactions yielding the active ingredient with molecular formula C<sub>20</sub>H<sub>27</sub>NO<sub>4</sub> and CAS No. <strong>154661-86-2</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing:</strong> Bulk API production for oral antidiabetic tablets.</li>
<li><strong>Clinical Therapy:</strong> Adjunct treatment for glycemic control when diet and exercise alone are insufficient.</li>
<li><strong>R&D Laboratories:</strong> Reference standard for bioequivalence studies and stability testing.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated in type 1 diabetes or diabetic ketoacidosis. Requires careful monitoring of blood glucose to prevent hypoglycemia, especially in elderly patients. Store API in sealed containers at controlled room temperature away from moisture and direct light.</p>